Author | Brandon Scalea | OncLive

Author | Brandon Scalea


BTK Inhibitors Show Continued Promise in CLL

July 16, 2019

Brian T. Hill, MD, PhD, highlights the latest data with BTK inhibitors in chronic lymphocytic leukemia.

Blood-Based Markers Key to Precision Medicine Approach in Breast Cancer

July 09, 2019

Mark E. Burkard, MD, PhD, discussed the significance of utilizing markers in the blood and highlighted emerging actionable mutations in breast cancer.

Dimopoulos Highlights Benefit of Elotuzumab Triplet in Relapsed/Refractory Myeloma

July 02, 2019

Meletios A. Dimopoulos, MD, discusses where the triplet combination of elotuzumab (Empliciti), pomalidomide (Pomalyst), and low-dose dexamethasone fits into the treatment paradigm of relapsed/refractory multiple myeloma and shared unanswered questions that remain in the space.

Adding PD-1 Inhibitor to Dabrafenib/Trametinib May Improve Outcomes in BRAF+ Melanoma

June 28, 2019

Ryan J. Sullivan, MD, discusses the success with dabrafenib (Tafinlar) plus trametinib (Mekinist) and highlights the potential added benefit of spartalizumab in BRAF-mutant with melanoma.